Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,406 across all filing types
Latest filing 2016-04-28 Report Publication Anno…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
CP en français
Report Publication Announcement Classification · 99% confidence The document is titled "PROCHAINS RENDEZ-VOUS INVESTISSEURS" (Upcoming Investor Meetings) and lists several conferences the company (Innate Pharma) will attend between May and June 2016. It also specifically announces an upcoming "Présentation R&D" (R&D Presentation) on May 16, 2016. This content is focused on communicating future engagement opportunities and presentations to the investment community, rather than releasing periodic financial results (ER/IR), announcing management changes (MANG), or detailing specific voting results (DVA). The closest fit among the provided categories is Investor Presentation (IP), as it details upcoming presentations and meetings where investor materials will be shared, although it is primarily an announcement of future events. Given the focus on announcing participation in investor conferences and a specific R&D presentation, 'Investor Presentation' (IP) is the most appropriate classification, as these events are where investor presentations occur.
2016-04-28 French
PR in English
AGM Information Classification · 99% confidence The document explicitly announces that Innate Pharma will hold its 'ANNUAL GENERAL MEETING OF SHAREHOLDERS' on June 2, 2016. It details the notice of meeting, agenda, proposed resolutions, and instructions for participation and voting. While it mentions the release of the 2015 Reference Document, the primary focus and subject of this press release is the upcoming AGM and the associated documentation/procedures. This aligns perfectly with the definition of 'AGM Information' (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2016-04-27 English
CP en français
AGM Information Classification · 98% confidence The document is titled "INNATE PHARMA ANNONCE LA TENUE DE SON ASSEMBLEE GENERALE ANNUELLE LE 2 JUIN 2016 A MARSEILLE ET LA MISE A DISPOSITION DE SON DOCUMENT DE REFERENCE 2015". The primary focus is the announcement of the date and details for the Annual General Meeting (AGM). Although it mentions the availability of the 'Document de Référence' (which contains the Annual Financial Report), the core purpose of this specific text is to announce the meeting itself, the agenda, and voting procedures. This aligns perfectly with the definition of AGM Information (AGM-R). It is not the full 10-K, nor is it a proxy statement (PSI) or a simple report publication announcement (RPA), as it contains substantive details about the meeting logistics.
2016-04-27 French
Document de référence 2015
Annual Report Classification · 100% confidence The document is explicitly titled 'DOCUMENT DE REFERENCE' and 'RAPPORT FINANCIER ANNUEL' (Annual Financial Report). It contains comprehensive financial statements, management discussion, governance details, and risk factors for the fiscal year 2015. In the context of French regulatory filings, the 'Document de Référence' serves as the equivalent of an Annual Report (10-K). FY 2015
2016-04-26 French
IPH AACR 2016 IPH52
Regulatory Filings Classification · 93% confidence The document is a press release dated April 19, 2016, announcing the presentation of preclinical data for a new drug candidate (IPH52) at the AACR Annual Meeting. It details scientific findings, includes quotes from management, and concludes with a reminder about an upcoming conference call for analysts to discuss the data. This structure—announcing scientific results and providing details about a subsequent call—is characteristic of an Earnings Release (ER) or a general press release related to operational/scientific updates. Since it is focused on scientific data presentation rather than quarterly financial performance highlights, and it explicitly announces a conference call to discuss the data, it aligns best with the 'Earnings Release' (ER) category, which often encompasses significant operational or scientific announcements that precede or accompany financial reporting periods, or the 'Call Transcript' (CT) if it were the transcript itself. Given the content is the announcement *leading up to* the call, ER is the closest fit for a major corporate update, although it is primarily scientific. However, the document also contains a specific section reminding recipients about the conference call details ('Time and dial in: Tuesday, April 19th 10:30am Eastern Time'). This structure strongly suggests it is an announcement intended to precede or accompany a discussion of results, fitting the 'Earnings Release' (ER) definition (initial announcement of periodical financial results/key highlights), even if the 'results' here are scientific data points rather than traditional quarterly financials. If the document were purely a scientific abstract, it might fit elsewhere, but the inclusion of management commentary and the explicit call reminder pushes it towards ER or CT. Since it is the announcement *of* the data and the call, ER is chosen over CT (which is the transcript itself).
2016-04-19 English
IPH AACR 2016 IPH52
Investor Presentation Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and details scientific data presented at the AACR congress regarding a new drug candidate (IPH52). It includes quotes from management, background information on the drug and companies, and contact details for press/investor relations. Crucially, it announces a conference call to discuss the data presented. This structure strongly indicates an announcement of scientific/research findings, which is often categorized as an Investor Presentation (IP) if it contains detailed scientific slides, or sometimes an Earnings Release (ER) if it's tied to a reporting period, but here it is focused purely on R&D data presentation at a conference. Given the detailed scientific content (posters #3222 and #3218) and the subsequent conference call announcement to discuss these results, 'Investor Presentation' (IP) is the most fitting category for disseminating detailed research updates to the investment community, even if the format is a press release announcing poster data. It is not a formal regulatory filing like 10-K or IR, nor is it a general earnings announcement (ER).
2016-04-19 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.